Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer is a research paper published in Journal of Geriatric Oncology (2021). On theSindex it has a DataRank of 0.430. It has been cited 7 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.118
From 6 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 7 citers.
National Institutes of Health
Grant: R03 AG050931-02
National Institutes of Health
Grant: K12CA001727
National Institutes of Health
Grant: 1R01CA206911-01A1
Targeting Chemotherapy-induced Breast Cancer Stemness
National Cancer Institute
Grant: P30CA033572
NCI NIH HHS
Grant: R01 CA206911
NIA NIH HHS
Grant: R03 AG050931
Eisai
Merck
Pfizer
FWCI
0.41
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals